...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics

Oops. Meant to say Phase 1 and 2 trials combined

"It is extremely well tolerated by patients, with safety data now exceeding 2700  patient  years." That comment is referring to patient years of patients treated with apabetalone. I don't have time to calculate how many apabetalone patient years were in the previous Phase 1/2 trials, but I will spit-ball that no more than 1000 patients were treated with apabetalone in past Phase 1 and 2 trials combined for no longer than 6 months, which would be 500 patient years. This 500 is likely an over-estimate. So this crude estimate suggests that Phase 3 BETonMACE has at least 2200 apabetalone patient years.

Share
New Message
Please login to post a reply